Description
Created On: 2020-07-15
Record Count: 4
Primary Industries
- Supply
- Medical
- Drugs
- cardiac
- Disease
- Therapeutic
- Pharmaceuticals
- Biotechnology
- Biological Materials
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 6732
The Licensee licensed from the Licensor the Stromal Cell technology for potential therapeutic use in the regrowth of damaged cardiac cells after a heart attack. The Licensor was formed by the Licensee President and its Chief Scientific Officer and Vice-President, to develop cellular technology for patients who have suffered myocardial infarctions.
The technology involves a method of preparing and using stromal cells for the treatment of cardiac diseases. A preferred embodiment of the technology is:
a) enriching unique cells from bone marrow samples;
b) expanding these cells using a proprietary patent-pending method; and
c) harvesting the stromal cell product for potential therapeutic use
IPSCIO Record ID: 294016
IPSCIO Record ID: 7028
In the event of bankruptcy, the rights to the Technology granted by the License revert to the Foundation.
Stromal cells are key components of tissues and provide critical cytokines and growth factors as well as the cellular microenvironment for normal homeostasis. A cytokine is a small protein released by cells that affects the interactions and communications between cells and the behavior of cells. A growth factor is a naturally occurring substance capable of stimulating cellular growth, proliferation and differentiation. Homeostasis is a self-regulating process by which a biological system maintains stability while adjusting to changing conditions. Stromal cells provide a niche proliferation environment for stem cells.
IPSCIO Record ID: 25793
LICENSED INVENTIONS means “Cardiogenic Cocktail for the production of Cardiac Cells†(Mayo Reference number MMV#2004-182) and “Stem Cell Based Therapy for Non-ischemic Cardiomyopathic Heart Failure†(Mayo Reference number MMV#2007-121). If not patented, then the Licensed Inventions are MAYO’s trade secret. To Mayo’s knowledge, the two inventions explicitly listed encompass Mayo’s inventions and intellectual property on guided cardiopoiesis as of the date of execution of the Second Amendment. Licensed Inventions also includes the following patent applications, and all divisionals, continuations and continuations in part based thereon, and any patents which may issue therefrom, and any reissues or extensions thereof (together, the “Licensed Patentsâ€) and know-how.
Licensed Inventions includes those patents listed below:
2007-121, Stem Cell Based Therapy for Non-ischemic Cardiomyopathic Heart Failure,
2004-182 Derivation of a Cardiopoetic Cellular Phenotype from a Stem Cell Source.
And the related Patents and Patent Applications;
06/592,871 Stem Cells and treatment of Vascular Tissue
06/680,775 Treating Cardiovascular Tissue
06/832,845 Methods and Materials for providing Cardiac Cells
PCT/US2005/026800 Treating Cardiovascular Tissue
PCT/US2008/064895 Methods and Materials for using Cells to treat Heart Tissue
PCT/US2009/044714 Compositions and Methods for Using Cells to treat Heart Tissue
PCT/US2009/044751 Methods for determining the Cardio Generative Potential of Mammalian Cells
The Licensee has developed C-Cure based on technology Licensed from the Licensor. In HF the heart is unable to pump enough blood to meet the body's metabolic needs. In the C-Cure process, stem cells are collected from an ischemic HF patient through bone marrow aspiration during an outpatient procedure. The stem cells are then harvested, selected, expanded and differentiated into cardiopoietic cells at our manufacturing facility, yielding a homogeneous and pure cardiopoietic cell population. The cardiopoietic cells are then re-injected into the heart of the ischemic HF patient with our C-Cathez cell injection catheter.